Vasundhara Rasayans Quarterly Results for Trading Insights
In Mar 2026, Vasundhara Rasayans (VRL) reported revenue ₹532 Cr and net profit ₹-16 Cr — revenue -31.3% YoY. For annual financials, live price and key ratios, visit VRL screener.
VRL Quarterly Results — Revenue, Profit & EPS Highlights
Vasundhara Rasayans latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse VRL shareholder distribution to track promoter, FII and institutional holdings.
- Revenue of ₹532 Cr in Mar 2026 (-31.3% vs Mar 2025, -31.3% vs Mar 2025)
- Net Profit of ₹-16 Cr in Mar 2026 (-1500.0% vs Mar 2025, -1500.0% vs Mar 2025)
- EBITDA of ₹9 Cr in Mar 2026 (-35.7% vs Mar 2025)
- Operating Margin of 2.0% in Mar 2026 (-1.0pp vs Mar 2025)
- Earnings Per Share of ₹-5.94 in Mar 2026 (-1348.8% vs Mar 2025)
Vasundhara Rasayans Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VRL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Mar 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 532 | 774 | 988 | -31.3% | -31.3% |
| Net Profit (₹ Cr) | -16 | -1 | 11 | - | - |
| EBITDA (₹ Cr) | 9 | 14 | 25 | - | - |
| EPS (₹) | -5.94 | -0.41 | 4.06 | - | - |
| Operating Margin (%) | 2.0% | 3.0% | 3.0% | - | - |
VRL Share Price Trend — 1-Year Movement Across Quarterly Results
Vasundhara Rasayans 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View VRL 52-week chart for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VRL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vasundhara Rasayans latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores